• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference

    4/7/25 4:05:00 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PLRX alert in real time by email

    SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that the Company will present three scientific posters at the upcoming 2025 American Thoracic Society (ATS) International Conference, taking place in San Francisco, California from May 16-21, 2025.

    The following abstracts are posted on ATS 2025's online itinerary planner for registered users.

    Pliant was selected for a featured oral presentation as part of the ATS 2025 Mini Symposiums program.

    Title: Characterizing the Antifibrotic Activity of Bexotegrast on Distinct Fibroblast Populations in PCLS From Multiple ILD Subtypes

    Presenter: Johanna Schaub, Ph.D., Director of Translational Sciences at Pliant Therapeutics

    Oral Presentation: 9696

    Session B98: Cellular interactions and signaling networks in pulmonary fibrosis (mini symposium)

    Date: Monday, May 19, 2025

    Presentation Time: 2:15 p.m. – 4:15 p.m. Pacific Time

    Title: Plasma Proteome Analysis Reveals Shared and Unique Biomarkers of ILD Subtypes

    Presenter: Richard Ahn, Ph.D., Senior Scientist II at Pliant Therapeutics

    Poster: 12006

    Session D29: From bench to bedside: unraveling pulmonary fibrosis through cellular communication and molecular pathways

    Date: Wednesday, May 21, 2025

    Presentation Time: 8:15 a.m. – 10:15 a.m. Pacific Time

    Title: Single-Cell Profiling Demonstrates the Antifibrotic Effects of Bexotegrast on Pathologic Lung Cell Populations in the Presence and Absence of Background Therapy

    Presenter: Mahru An, Ph.D., Principal Scientist at Pliant Therapeutics

    Poster: 12106

    Session D29: From bench to bedside: unraveling pulmonary fibrosis through cellular communication and molecular pathways

    Date: Wednesday, May 21, 2025

    Presentation Time: 8:15 a.m. – 10:15 a.m. Pacific Time

    Posters will be available to view during the ATS Conference, Sunday, May 18 - Wednesday, May 21 during the above times for registered users and on the Presentations page of the company website at www.PliantRx.com.

    About Pliant Therapeutics, Inc.

    Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or IPF. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and Orphan Drug Designation from the European Medicines Agency in IPF. Pliant is conducting a Phase 1 study for PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α7β1 targeting muscular dystrophies.

    For additional information, please visit: www.PliantRx.com. Follow us on social media X, LinkedIn, and Facebook.

    Investor and Media Contact:

    Christopher Keenan

    Vice President, Investor Relations and Corporate Communications

    Pliant Therapeutics, Inc.

    [email protected]



    Primary Logo

    Get the next $PLRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PLRX

    DatePrice TargetRatingAnalyst
    3/4/2025Buy → Hold
    Needham
    3/4/2025Neutral
    Cantor Fitzgerald
    3/3/2025Buy → Hold
    Stifel
    3/3/2025Outperform → Market Perform
    Leerink Partners
    2/10/2025Overweight → Neutral
    Analyst
    2/10/2025$43.00 → $4.00Buy → Hold
    Canaccord Genuity
    2/10/2025Outperform → Perform
    Oppenheimer
    2/10/2025$40.00 → $4.00Buy → Neutral
    Citigroup
    More analyst ratings